BioCentury | Feb 26, 2020
Emerging Company Profile

WindMIL: T cell source is key

...a single antigen -- CD19. Patients can relapse if CD19-negative tumor cells evade treatment, Patrick Dougherty...
...MILs are naturally polyantigen specific, they recognize more than one antigen on the cell surface,” Dougherty...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...Dougherty to SVP of strategy, planning and operations. LaRochelle was CBO of PsiOxus Therapeutics Ltd.; Dougherty...
BioCentury | Jul 20, 2018
Financial News

Provention raises $64M IPO

...of 16 million shares at $4 in an IPO underwritten by MDB Capital Group and Dougherty...
BioCentury | Jul 20, 2018
Financial News

Provention raises $64M IPO

...of 16 million shares at $4 in an IPO underwritten by MDB Capital Group and Dougherty...
BioCentury | Jun 21, 2017
Company News

Management tracks

...Merrimack Pharmaceuticals Inc. (NASDAQ:MACK). Stapled peptide therapeutics company Aileron Therapeutics Inc. (Cambridge, Mass.) named Donald Dougherty...
BioCentury | Oct 26, 2015
Financial News

WaferGen completes follow-on

...1,500 Price: $10,000 (unit) Shares after offering: 11.9 million Underwriters: Ladenburg Thalmann; Chardan Capital Markets; Dougherty...
BioCentury | Sep 28, 2015
Financial News

WaferGen amends follow-on

...Up to $20 million Units: 2,000 Price prior: $1.31 Underwriters: Ladenburg Thalmann; Chardan Capital Markets; Dougherty...
...amended its offering and proposed to sell 2,000 units. The company also added Chardan and Dougherty...
BioCentury | Sep 8, 2014
Finance

Banker tracks

...tracks Joseph Dougherty, founder and managing director of Seaview Securities, passed away late last month. Dougherty's...
BioCentury | Nov 4, 2013
Financial News

Cancer Genetics completes follow-on

...3.3 million Price: $14 Shares after offering: 9.3 million Underwriters: Aegis Capital; Feltl; Cantor Fitzgerald; Dougherty...
BioCentury | Oct 29, 2013
Financial News

Cancer Genetics closes $46 million follow-on

...total raised includes 428,700 shares sold in the overallotment. Aegis Capital; Feltl; Cantor Fitzgerald; and Dougherty...
Items per page:
1 - 10 of 56
BioCentury | Feb 26, 2020
Emerging Company Profile

WindMIL: T cell source is key

...a single antigen -- CD19. Patients can relapse if CD19-negative tumor cells evade treatment, Patrick Dougherty...
...MILs are naturally polyantigen specific, they recognize more than one antigen on the cell surface,” Dougherty...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...Dougherty to SVP of strategy, planning and operations. LaRochelle was CBO of PsiOxus Therapeutics Ltd.; Dougherty...
BioCentury | Jul 20, 2018
Financial News

Provention raises $64M IPO

...of 16 million shares at $4 in an IPO underwritten by MDB Capital Group and Dougherty...
BioCentury | Jul 20, 2018
Financial News

Provention raises $64M IPO

...of 16 million shares at $4 in an IPO underwritten by MDB Capital Group and Dougherty...
BioCentury | Jun 21, 2017
Company News

Management tracks

...Merrimack Pharmaceuticals Inc. (NASDAQ:MACK). Stapled peptide therapeutics company Aileron Therapeutics Inc. (Cambridge, Mass.) named Donald Dougherty...
BioCentury | Oct 26, 2015
Financial News

WaferGen completes follow-on

...1,500 Price: $10,000 (unit) Shares after offering: 11.9 million Underwriters: Ladenburg Thalmann; Chardan Capital Markets; Dougherty...
BioCentury | Sep 28, 2015
Financial News

WaferGen amends follow-on

...Up to $20 million Units: 2,000 Price prior: $1.31 Underwriters: Ladenburg Thalmann; Chardan Capital Markets; Dougherty...
...amended its offering and proposed to sell 2,000 units. The company also added Chardan and Dougherty...
BioCentury | Sep 8, 2014
Finance

Banker tracks

...tracks Joseph Dougherty, founder and managing director of Seaview Securities, passed away late last month. Dougherty's...
BioCentury | Nov 4, 2013
Financial News

Cancer Genetics completes follow-on

...3.3 million Price: $14 Shares after offering: 9.3 million Underwriters: Aegis Capital; Feltl; Cantor Fitzgerald; Dougherty...
BioCentury | Oct 29, 2013
Financial News

Cancer Genetics closes $46 million follow-on

...total raised includes 428,700 shares sold in the overallotment. Aegis Capital; Feltl; Cantor Fitzgerald; and Dougherty...
Items per page:
1 - 10 of 56